JNJ news

Latest 20 stories · newest Nov 6, 2026

JNJ
Reported Earlier, FDA Grants J&J Accelerated Approval For Rybrevant Faspro In Advanced Head And Neck Squamous Cell Carcinoma, Based On OrigAMI-4 Phase 1b/2 Trial Showing 42% Overall Response Rate
News Nov 6, 2026 sentiment +0.50 Source: benzinga.com ↗
JNJ
First Therapy for Advanced Head & Neck Cancer in 10 Years: Johnson & Johnson Secures Accelerated FDA Nod
Movers Nov 6, 2026 sentiment +0.75 Source: benzinga.com ↗
JNJ
FDA Grants Accelerated Approval To Rybrevant Faspro For Recurrent Or Metastatic Head And Neck Squamous Cell Carcinoma
Biotech Nov 5, 2026 sentiment +0.50 Source: benzinga.com ↗
JNJ
Reported Earlier: 'J&J's trispecific, Tibsovo's AML Win And Calquence's CLL Letdown As First ASH Abstracts Land' - Endpoints News
Biotech Nov 4, 2026 sentiment -0.30 Source: benzinga.com ↗
JNJ
Jim Cramer Likes This Industrial Stock: ‘It’s Come Down A Great Deal’
Markets Nov 3, 2026 sentiment +0.10 Source: benzinga.com ↗
JNJ
Reported Sunday, Johnson & Johnson Says Impella Outcomes Depend On Patient Selection, Timing And Post-Procedural Care, Citing Lower Mortality In Three TCT Analyses Versus CHIP-BCIS3; PROTECT IV Results Expected 2027
News Nov 2, 2026 sentiment 0.00 Source: benzinga.com ↗
JNJ
Coca-Cola, Boeing And 3 Stocks To Watch Heading Into Tuesday
Markets Oct 27, 2026 sentiment 0.00 Source: benzinga.com ↗
JNJ
Nasdaq Gains Over 200 Points As Chip Stocks Rise: Investor Sentiment Improves, Fear & Greed Index Moves To ‘Fear’ Zone
Markets Oct 27, 2026 sentiment 0.00 Source: benzinga.com ↗
JNJ
Johnson & Johnson Plans To Hold Enterprise Business Review On Dec. 8
News Oct 27, 2026 sentiment 0.00 Source: benzinga.com ↗
JNJ
Mark Cuban Warns CEOs If Your Health Benefits Do Not Actually Help Employees You Are Legally Liable - 'It’s All On You’
Health Care Oct 26, 2026 sentiment -0.30 Source: benzinga.com ↗
JNJ
Johnson & Johnson Announced Sunday at ESMO, Phase 1b/2 OrigAMI-4 Data Showing 77% Response Rate, 14% Complete Responses With RYBREVANT Combination In First-Line HNSCC
News Oct 25, 2026 sentiment +0.70 Source: benzinga.com ↗
JNJ
Johnson & Johnson Announced At ESMO Saturday, Phase 3 PROTEUS Substudy Data Showing Perioperative Apalutamide Plus ADT Reduced Risk Of Disease Recurrence Or Death By 62%, Metastasis Or Death By 51% Vs. Surgery Alone In High-Risk Prostate Cancer
News Oct 25, 2026 sentiment +0.50 Source: benzinga.com ↗
JNJ
Johnson & Johnson's Icotrokinra Hydrochloride Receives Medicines And Healthcare Products Regulatory Agency Approval To Treat Moderate To Severe Plaque Psoriasis
News Oct 23, 2026 sentiment +0.20 Source: benzinga.com ↗
JNJ
Johnson & Johnson Announces Data From Its VARIPURE, Omny-IRE Trials Demonstrated 100% Of Participants Had Acute Procedural Success; Mean Ablation Rate Of 17.9 Minutes Observed
News Oct 22, 2026 sentiment +0.20 Source: benzinga.com ↗
JNJ
Johnson & Johnson Announces U.S. Launch Of Shockwave C2 Aero Fly Coronary Catheter, Says It Halves Treatment Time
News Oct 20, 2026 sentiment +0.20 Source: benzinga.com ↗
JNJ
Johnson & Johnson Announces 1-Yr Results From Phase 3 FUZION Study Showing TREMFYA Maintained Or Improved Fistula Remission Through 48 Weeks In Adults With Crohn's Disease
News Oct 19, 2026 sentiment +0.50 Source: benzinga.com ↗
JNJ
Committee For Medicinal Products For Human Use Recommends Approval Of Indication Extension Of Johnson & Johnson's TALVEY To Treat Adults With Relapsed Or Refractory Multiple Myeloma
News Oct 16, 2026 sentiment +0.40 Source: benzinga.com ↗
JNJ
Wells Fargo Maintains Overweight on Johnson & Johnson, Raises Price Target to $287
Analyst Ratings Oct 16, 2026 sentiment +0.50 Source: benzinga.com ↗
JNJ
Morgan Stanley Maintains Overweight on Johnson & Johnson, Lowers Price Target to $292
Analyst Ratings Oct 15, 2026 sentiment +0.10 Source: benzinga.com ↗
JNJ
Bank of America, Johnson & Johnson, Six Flags Entertainment, Citigroup and Applied Materials: Why These 5 Stocks Are on Investors' Radars Today
Markets Oct 14, 2026 sentiment 0.00 Source: benzinga.com ↗
BriefTape provides AI-summarized public SEC filings for informational purposes only. Content does not constitute investment advice. Always verify against source filings at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.

The same JNJ feed as JSON for your bot or app:

GET https://api.brieftape.com/v1/tickers/JNJ/newsSTART FREE